Latest Safety News

SSH Group has landed a $2.53 million strategic placement from Hong Kong Xinhai Mining Services, marking a pivotal step in its evolution into a vertically integrated mining powerhouse.

Service Stream has delivered a robust FY25 performance with revenue growth, record profits, and a landmark $1.6 billion Defence contract, setting the stage for continued expansion.

Evergreen Lithium has secured key regulatory approvals to begin reverse circulation drilling at its Mt Monger Gold Project, targeting high-potential gold prospects Duchess of York and Kiaki Soaks. The campaign aims to unlock valuable insights and guide further exploration in 2026.

BPM Minerals has secured the Forelands Gold Project with promising high-grade intercepts and divested its Claw Gold Project to Capricorn Metals, bolstering its cash position ahead of upcoming drilling.

Ora Banda Mining Ltd reported a record September quarter with a 39% surge in gold production and a 37% rise in gold sales, underpinned by strong operational performance and exploration success.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Challenger Gold has secured critical drilling and explosives contracts and completed refurbishment of the Casposo Toll Milling plant, marking a pivotal step toward early gold production at its Hualilán project in Argentina.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Pilot Energy has secured crucial environmental approval to conduct a 3D seismic survey offshore Perth Basin, propelling its exploration and farmout ambitions forward while supporting carbon storage initiatives.

Veris Limited has reversed its FY24 loss to post a $2.0 million profit before tax in FY25, driven by digital growth and strategic acquisitions. The company’s focus on higher-margin consulting and advisory services underpins a positive outlook for FY26.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.